|
Small
cell carcinoma with concomitant adenocarcinoma arising in a Barrett's
oesophagus: report of a case with a favourable behaviour.
Virchows Arch. 2008 Jan;452(1):103-107. Epub 2007 Nov 16.
Most Barrett's
oesophagus-associated cancers are adenocarcinomas which occur in a pure
form. They are rarely combined with another type of malignancy, such as
endocrine tumours. Within the endocrine spectrum, small cell carcinomas (SmCC)
usually have a highly aggressive behaviour with a poor prognosis. We report
a case of composite SmCC and adenocarcinoma in the setting of a Barrett's
oesophagus, in a 54-year-old man. This tumour was identified on a surgical
specimen after neoadjuvant treatment with radiotherapy and 5-FU-Cis-platin
based chemotherapy. The SmCC component was positive for chromogranin A,
synaptophysin, neural cell adhesion molecule and neuron-specific enolase and
negative for high molecular weight cytokeratin. The adenocarcinoma component
showed a converse phenotype. In our case, the origin of the SmCC component
could be explained by the numerous chromogranin A-positive cells observed in
the Barrett's oesophagus or by the potential progenitor cells that may be
located in the submucosal oesophageal gland ducts and the Barrett's
metaplasia. Our report is thus indicative of the high and totipotential risk
of Barrett's oesophagus. Moreover, it is particular because of its
favourable behaviour, with a 6-year disease-free survival, after neoadjuvant
chemoradiation, surgery and postoperative chemotherapy.
Small cell carcinoma of the
esophagus: report of a case with review of the literature.J
BUON. 2002 Apr-Jun;7(2):161-4.
Primary small-cell
carcinoma of the esophagus is a rare tumor that disseminates early and has a
uniformly poor prognosis if untreated. We report on a patient with
esophageal small-cell carcinoma treated with combination chemotherapy
following surgical resection. A 48-year-old female had an ulcerated tumor in
the distal part of the esophagus, which was microscopically diagnosed as
esophageal small-cell carcinoma. Computed tomography (CT) of the chest and
abdomen showed no lymphadenopathy or distant metastatic disease.
Chemotherapy plus radiation therapy was planned but the patient refused the
proposed treatment due to socieconomic reasons. Subsequently, subtotal
esophagectomy with lymphadenectomy (3 periesophageal nodes) was performed in
another hospital. The histopathologic diagnosis of the primary tumor was
small-cell carcinoma and the resected lymph nodes also contained metastatic
deposits. On the second postoperative month she was admitted with hepatic
metastases. Combination chemotherapy with etoposide 120 mg/m(2)/day on days
1 to 3, and cisplatin 75mg/ m(2)/day on day 1, given intravenously (i.v.)
every 3 weeks was started. After 3 courses, the patient achieved complete
remission. Esophageal small-cell carcinoma is an aggressive tumor. Patients
with disseminated disease should receive combination chemotherapy along with
symptomatic treatment. |